1 0 gene-disease relationship, and the subsequent validation of this framework using a set 1 1 of representative gene-disease pairs. The framework provides a semi-quantitative 1 2 measurement for the strength of evidence of a gene-disease relationship which 1 3 correlates to a qualitative classification: "Definitive", "Strong", "Moderate", "Limited", "No 1 4 Reported Evidence" or "Conflicting Evidence." Within the ClinGen structure, 1 5 classifications derived using this framework are reviewed and confirmed or adjusted 1 6 based on clinical expertise of appropriate disease experts. Detailed guidance for 1 7 utilizing this framework and access to the curation interface is available on our website. 1 8 This evidence-based, systematic method to assess the strength of gene-disease 1 9 relationships will facilitate more knowledgeable utilization of genomic variants in clinical 2 0 and research settings. The human genome comprises approximately 20,000 protein-coding genes 1 , of which 3 about 3,000 have been reported in association with at least one Mendelian disease 2 . 4 Roughly half 2 of these gene-disease relationships have been identified over the last 5 decade, as technological advances have made it possible to use sequence information 6 from small families or even single individuals to discover new candidate gene-disease 7 relationships 3; 4 . However, there is substantial variability in the level of evidence 8 supporting these claims, and a systematic method for curating and assessing evidence 9 is needed. Despite this variability, clinical laboratories may include genes with preliminary evidence 1 1 of a gene-disease relationship on disease-targeted panels, or in results returned from 1 2 exome/genome sequencing. Some of the gene-disease relationships are either unable 1 3 to be confirmed for many years or are ultimately proven wrong 5 . Evaluating the clinical 1 4 impact of variants identified in genes with an unclear role in disease is exceedingly 1 5 difficult, and could lead to incorrect diagnoses, preventing further evaluations and/or gene-disease association in subsequent independent publications and additional 1 substantial genetic and experimental data are critical factors for the "Strong" 2 classification. Finally, the hallmark of a "Definitive" gene-disease association is that, in 3 addition to the accumulation of convincing genetic and experimental evidence, the 4 relationship has been replicated, and ample time has passed since the initial publication 5 (in general, greater than three years) for any conflicting evidence to emerge. It is 6 important to highlight that these classifications do not reflect the effect size or relative 7 risk attributable to variants in a particular gene, but instead the strength of the evidence. 8 For example, a definitive gene-disease association does not imply that a pathogenic 9 variant in that gene confers 100% penetrance of the phenotype. This metric is not 1 0 intended to assess the penetrance or risk to develop a disease outcome. 1 1 A gene-disease relationship can be determined to have one of the above classifications 1 2 provided no substantial relevant and valid contradictory evidence exists to call the gene- 1 3 disease relationship into question. If such evidence emerges, then the relationship is 1 4 described as "Conflicting Evidence Reported." Types of contradictory evidence may 1 5 come from population studies (such as ExAC 9 ), attempts to experimentally validate the 1 6 gene-disease association, or re-analysis of the original family or cohort that was 1 7 previously studied. Although the role of a specific variant in a given disease may be 1 8 called into question by new evidence, this may not be sufficient to invalidate the role of 1 9 the gene in that disease. Thorough evaluation by experts in the particular disease area 2 0 is recommended to determine whether the contradictory evidence outweighs the 2 1 existing supportive evidence to classify a gene into either a "Disputed" or "Refuted" 2 2 category (see Figure 1 for additional details). 1 Assigning a clinical validity classification to a gene-disease pair requires assessment of 2 the evidence supporting the association. We developed a semi-quantitative approach to 3 evaluate both genetic ( Figure 2 ) and experimental evidence ( Figure 3 ) in a standardized 4 manner that promotes consistent collection and weighting of evidence (a detailed 5 standard operating procedure is available on the ClinGen website). Defined sub- 6 categories of genetic and experimental evidence are given a suggested default "score." 7 However, given that evidence of the same general type may vary in its strength 8 (particularly when considering different diseases), the scoring system also allows these 9 scores to be adjusted within a set range of points, with final approval by experts within 1 0 the particular disease domain. Finally, the maximum number of points allowed for the 1 1 various types of genetic and experimental evidence is capped to prevent a 1 2 preponderance of weak evidence from inappropriately inflating the gene-disease 1 3 classification. Similarly, certain evidence categories are provided higher maximum 1 4 scores, allowing key pieces of stronger evidence to proportionately influence the 1 5 classification of a gene-disease pair. 1 6 Genetic Evidence 1 7 For the purposes of scoring, genetic evidence is divided into two categories: case-level 1 8 data and case-control data ( Figure 2 ). Studies describing individuals or families with 1 9 genetic variants are scored as case-level data, while studies using statistical analyses to compare variants in cases and controls are scored as case-control data. When case- 2 1 level and case-control data are present in a single publication, points can be assigned in 2 2 each category, but the same piece of evidence should not be counted more than once. 1 For example, an individual case that is also included within a case-control cohort should 2 not be given points in both the "case-level data" and "case-control data" categories. In 3 this scenario, points should be assigned to the most compelling and informative 4 evidence.
METHODS: SEMI-QUANTITATIVE ASSESSMENT OF EVIDENCE

5
Assessing case-level data requires consideration of the inheritance pattern and 6 evaluation of the individual variants identified in each case. Within this framework, a 7 case should only be counted towards supporting evidence if the reported variant has 8 some indication of a potential role in disease (e.g., impact on gene function, recurrence 9 in affected individuals, etc.), does not have evidence that would contradict pathogenicity 1 0 (e.g., population allele frequency), and is of the type consistent with the assumed 1 1 disease mechanism (e.g. truncating variant for loss of function). Unless otherwise 1 2 noted, the term "qualifying variant" implies that these criteria are met. In addition, points 1 3 are assigned separately for segregation data to reflect the statistical probability that the 1 4 locus is implicated in the disease. Figure 2 and Figure S1 provide guidance on the 1 5 number of points that should be considered for segregation evidence by LOD score; if a 1 6 LOD score is not provided within the publication being evaluated, an estimated LOD 1 7 score may be calculated in certain scenarios, as described in the standard operating 1 8 procedure document provided on the ClinGen website. 1 9 Each study categorized as "case-control data" should be independently assessed to evaluate the quality of the study design (see Figure 2 ). Consultation with a clinical 2 1 domain expert group (such as those affiliated with ClinGen, 2 2 https://www.clinicalgenome.org/working-groups/clinical-domain/) is recommended. For to controls. More than one variant may be analyzed, but the variants have been 4 independently assessed with appropriate statistical correction for multiple testing. 5 Aggregate variant analyses are those in which the total number of variants is assessed 6 for enrichment in cases compared with controls. This comparison is typically 7 accomplished by sequencing the entire gene in both cases and controls and 8 demonstrating an increased "burden" of variants of one or more types. The experimental data scoring system is presented in Figure 3 . The gene-level 1 1 experimental data used in this framework to assess a gene-disease association are 1 2 consistent with those proposed by MacArthur and colleagues to implicate a gene in 1 3 disease 10 . The following experimental evidence types are used: biochemical function, 1 4 experimental protein interactions, expression, functional alteration, phenotypic rescue 1 5 and model systems ( Figure 3 bottom panel). These categories capture the most 1 6 relevant types of experimental information necessary to determine whether the function 1 7 of the gene product is at least consistent with the disease with which it is associated, if 1 8 not causally implicated. While curators are encouraged to seek out and document (via qualitative description) 2 1 conflicting evidence, no specific points are assigned to this category. The types of valid 2 2 contradictory evidence and their relative weights will be unique to each gene-disease 1 pair, and it would be misleading to attempt to uniformly quantify this type of negative 2 evidence against the reported positive evidence. If there is substantial conflicting The scores assigned to both genetic and experimental evidence are tallied to generate 9 a total score (ranging from 1-18) that corresponds to a preliminary clinical validity 1 0 classification ( Figure 4) . The system provides a transparent method for summarizing 1 1 and assessing all curated evidence for a gene-disease pair, encouraging consistency 1 2 between curators. While the summary matrix facilitates a preliminary assessment of the 1 3 gene-disease relationship, the initial curator or expert reviewer may adjust the 1 4 classification, supplying a specific rationale for the change. Final classifications are 1 5 determined in collaboration with disease experts, who review the preliminary 1 6 classification and supporting evidence and work to come to a consensus with the 1 7 preliminary curators. In the event that the disease experts and preliminary curators 1 8 disagree on a final classification, a senior member of the ClinGen Gene Curation 1 9 Working Group may be brought in to facilitate a final classification, erring towards the 2 0 more conservative classification if consensus cannot be achieved. It should be noted 2 1 that experimental data alone cannot justify a clinical validity classification beyond "No 2 2 Reported Evidence," and at least one human genetic variant with a plausible causal 2 3 association must be present to attain "Limited" classification. The difference between 1 "Limited," "Moderate," and "Strong" gene-disease classifications is justified by the 2 quality and quantity of evidence; it is expected that valid gene-disease associations will 3 gradually accumulate enough supporting evidence and be replicated over time to attain 1 1 Using this framework we evaluated 33 gene-disease pairs representing a variety of 1 2 disease domains and spanning the spectrum of clinical validity classifications (see 1 3 Table 1, Figure 5 , and Supplemental Appendix). To assess the reproducibility of our 1 4 scoring metric, each gene-disease pair was evaluated by two independent curators; (93.5%) gene-disease pairs with available published evidence ( Figure 5 ; associations 1 7 classified as "No Reported Evidence" were excluded). Each gene-disease pair was 1 8 subsequently reviewed by clinical domain experts; experts agreed with the preliminary each different by only a single category (e.g. limited versus moderate). Of note, the 2 2 original classifications for HNRNPK (MIM 600712) and SMARCA1 (MIM 300012) were 2 3 at the border between limited and moderate (6.5 points); in each case, the preliminary 1 curators' lack of specific clinical expertise led to uncertainty regarding the scoring of 2 evidence requiring such knowledge. Consulting with clinical experts in the disease 3 resolved these issues resulting in both genes being upgraded to moderate. In the case 4 of WRAP53 (MIM 612661), the expert was aware of additional published experimental 5 evidence that when included increased the classification from limited to moderate. Upon Appendix. The evidence-based framework described here qualitatively defines clinical validity 1 5 classifications for gene-disease associations in monogenic conditions and provides a 1 6 systematic framework for evaluating key criteria required for these classifications. This 1 7 method is intentionally flexible to accommodate curation of a wide spectrum of genes 1 8 and conditions by curators with varying levels of expertise. The semi-quantitative 1 9 scoring system combined with the qualitative classification scheme guides curators 2 0 through the preliminary decision-making process, while the expert-level review provides 2 1 disease-specific experience to weigh in on the final classification. 2 2 This effort to create a generalized framework may result in some specific challenges 1 due to the heterogeneity of genetic conditions, in both phenotype and prevalence. For mutational mechanisms. This is a topic of continued discourse within the ClinGen 1 1 working groups and will be incorporated into future manuscripts that will focus on the 1 2 curation approach for individual ClinGen disease-focused expert groups. 1 3 Ultra-rare disorders may have a relatively small number of probands described in the 1 4 medical literature, thus limiting their potential to achieve a high genetic evidence score 1 5 within this matrix. This obstacle is mostly circumvented by allowing compelling pieces of 1 6 genetic evidence to score the maximum number of points (for example, see CD3E (MIM 1 7 186830) and severe combined immunodeficiency (MIM 615615), detailed in the 1 8 Supplemental Appendix). When substantial experimental evidence is also available, 1 9 these conditions can attain a "Strong" or "Definitive" classification. On the opposite end of the spectrum are conditions that occur commonly in the general population, such as 2 1 cancer, where the predominant etiology is multifactorial rather than monogenic. In the 2 2 less common Mendelian cancer predisposition syndromes, incomplete penetrance is a 2 3 typical feature that can lead to confounding factors in family genetic studies such as 1 apparently non-penetrant family members who carry a disease-associated variant and 2 phenocopies among family members without a disease-associated variant. For such 3 conditions, case-control data may provide more compelling evidence to support the 4 gene-disease association (see the curation of PALB2 (MIM 610355) and hereditary 5 breast cancer (MIM 114480) in the Supplemental Appendix as an example). 6 One limitation of any such system is the challenge of balancing thorough literature 7 curation and practical time commitment. This system can accommodate an exhaustive 8 literature review, but in most cases will only require curating the amount of information 9 sufficient to reach the maximum number of points in the matrix. In some scenarios this 1 0 method may fail to include pertinent information, which could impact the classification 1 1 (e.g., omission of contradictory evidence). Another potential limitation is the subjective 1 2 nature of certain evidence types (e.g., experimental), which may lead to variability 1 3 between different groups assessing evidence. However, due to the transparency of the 1 4 evidence base, the incorporation of expert review, and the ability to reassess 1 5 classifications over time, such drawbacks are likely to be self-limiting. 1 6 ClinGen's ultimate goal is to enhance the incorporation of genomic information into 1 7 clinical care, an important component of the Precision Medicine Initiative 13 . The 1 8 implementation of this framework will be supported by an open-access ClinGen curation 1 9 interface (under development) that will guide curators through the curation process and 2 0 will serve as a platform for extension to the community. In essence, this framework aims 2 1 to provide a systematic, transparent method to evaluate a gene-disease relationship in 2 2 an efficient and consistent manner suitable for a diverse set of users. A detailed 2 3 standard operating procedure for this framework is available on the ClinGen website. All 1 curated evidence, including clinical validity assessments, will also be made readily 2 accessible to clinical laboratories, clinicians, researchers, and the community via our 3 website. Additionally, for community members that wish to contribute papers of interest 4 and/or request curation of a gene-disease pair, a "reporter" form is available on the 5 ClinGen website. 6 Carefully evaluated gene-disease clinical validity classifications, as provided by this 7 framework, will be useful to clinical laboratories as they evaluate genes for inclusion on 8 disease-targeted panels, or as they decide how to categorize, prioritize, and return 9 results from exome/genome sequencing. Clinicians may choose to use these types of 1 0 gene-disease classifications as they interpret laboratory results for the individuals they 1 1 care for; for instance, they may choose not to adjust medical management based on 1 2 variants in genes of limited clinical validity. Researchers could also utilize this 1 3 framework to evaluate the clinical validity of their own newly discovered associations 1 4 and identify promising target genes for future work in order to augment the currently 1 5 available evidence and attain a "Strong" or "Definitive" classification. In addition, 1 6 professional societies and regulatory bodies may utilize these clinical validity 1 7 assessments when making recommendations or guidelines for clinical genetic testing. 1 8 Ultimately, our systematic, evidence-based method for evaluating gene-disease 1 9 associations will provide a strong foundation for genomic medicine. 1 The Supplemental file includes one figure, an appendix with curated evidence for each 2 example presented in Figure 5 , and a list of references. A more comprehensive 3 supplemental file is available on the BioRxIV preprint server (see doi: the NIH, National Library of Medicine. We would like to thank the following groups and Savage, M.D.; Fergus J. Couch Ph.D. and the ClinGen Hereditary Breast and Ovarian 1 7 Cancer gene curation working group; Birgit H. Funke Ph.D. and the ClinGen 1 8 Cardiomyopathy gene curation working group; and the ClinGen RASopathy curation 1 9 working group. Input on the framework was also provided by the ClinGen Hereditary Gollob and the ClinGen Channelopathy gene curation working group. We would also Standard operating procedure for the framework described in this manuscript: ClinGen clinical validity framework. For additional points to consider when scoring 1 2 genetic evidence, please see the standard operating procedure document available on 1 3 our website. Genetic evidence is separated into two main categories: case-level data 1 4 and case-control data. While a single publication may include both case-level and case- 1 5 control data, individual cases should NOT be included in both categories. Each category 1 6 is assigned a range of points with a maximum score that can be achieved. Case-Level 1 7 Data is derived from studies describing individuals and/or families with qualifying 1 8 variants in the gene of interest. Points should be assigned to each case based on the 1 9 variant's inheritance pattern, molecular consequence and evidence of pathogenicity in disease. In addition to variant evidence points, a gene-disease pair may also receive 2 1 points for compelling segregation analysis (see Figure S1 ). Case-Control Data: Studies 2 2 utilizing statistical analysis to evaluate variants in cases compared to controls. Case- 2 3 control studies can be classified as either single variant analysis or aggregate variant 1 analysis, however the number of points allowable for either category is the same. Points 2 should be assigned according to the overall quality of each study based on these 3 criteria: variant detection methodology, power, bias and confounding factors, and 4 statistical power. Note that the maximum total scores allowed for different types of 5 Case-Level data are not intended to add up to the total points allowed for Genetic 6 Evidence as a whole. This permits different combinations of evidence types to achieve 7 the maximum total score. Evidence types are divided into three categories based on their relative contribution to 1 2 the overall clinical validity of a gene-disease pair giving more weight to in vivo data. 1 3 Each category is assigned a range of points with a maximum score that can be 1 4 achieved, allowing more weight to be given to in vivo data (e.g. Models & Rescue) over 1 5 in vitro experimental data. Evidence within the function category is given the least 1 6 weight and is comprised of the following types of evidence: biochemical function, 1 7 interactions, and expression. Functional alteration experiments in cells from affected 1 8 individuals carrying candidate pathogenic variants are given more weight than the 1 9 function category. Finally, model systems and phenotypic rescue experiments are given 2 0 the most weight in our framework. Note that the maximum total scores allowed for than three years has passed since the publication of the first paper reporting the gene- 1 1 disease relationship AND more than two publications with human mutations exist. 1 2 Contradictory Evidence -No points are assigned to this category. Instead, the curator 1 3 should provide a summary of contradictory information. Scoring -The sum of the 1 4 quantified evidence from each category can be used to determine a "provisional" 1 5 classification using the scale at the bottom of the figure. If a curator does not agree with 1 6 this classification, he/she may provide a different suggested classification along with 1 7 appropriate justification. curation framework, 31 were classified using the summary matrix (2 gene-disease pairs, 2 2 PMS2:pancreatic cancer and ARSD:chondrodysplasia punctata, were classified as "No 2 3 evidence reported" and are not shown). Genetic evidence (grey bars) and experimental 1 evidence (black bars) were evaluated by two independent curators (C1-C9) to arrive at 2 a provisional classification (x-axis). Gene-disease relationships scoring between 12-18 3 points can be "Strong" or "Definitive," depending on whether the association has been 
RESULTS: VALIDATION OF METHOD
DESCRIPTION OF SUPPLEMENTAL DATA:
Evidence Level
Evidence Description
Supportive Evidence
DEFINITIVE
The role of this gene in this particular disease has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time (in general, at least 3 years). No convincing evidence has emerged that contradicts the role of the gene in the specified disease.
STRONG
The role of this gene in disease has been independently demonstrated typically in at least two separate studies providing strong supporting evidence for this gene's role in disease, usually including both of the following types of evidence:
• Strong variant-level evidence demonstrating numerous unrelated probands with variants that provide convincing evidence for disease causality 1 as well as
• Compelling gene-level evidence from different types of supporting experimental data 2 .
In addition, no convincing evidence has emerged that contradicts the role of the gene in the noted disease.
MODERATE
There is moderate evidence to support a causal role for this gene in this disease, typically including both of the following types of evidence:
• Several probands with variants that provide convincing evidence for disease causality 1 • Moderate experimental data 2 supporting the gene-disease association
The role of this gene in disease may not have been independently reported, but no convincing evidence has emerged that contradicts the role of the gene in the noted disease.
LIMITED
There is limited evidence to support a causal role for this gene in this disease, such as:
• Fewer than three observations of variants that provide convincing evidence for disease causality 1 OR
• Variants have been observed in probands, but none have sufficient evidence for disease causality. • Limited experimental data 2 supporting the gene-disease association
NO REPORTED EVIDENCE
Evidence for a causal role in disease has not been reported. These genes might be "candidate" genes based on linkage intervals, animal models, implication in pathways known to be involved in human diseases, etc., but no reports have directly implicated the gene in human disease cases.
Contradictory Evidence
CONFLICTING EVIDENCE REPORTED
Although there has been an assertion of a gene-disease association, conflicting evidence for the role of this gene in disease has arisen since the time of the initial report indicating a disease association. Depending on the quantity and quality of evidence disputing the association, the association may be further defined by the following two sub-categories: 1. Disputed a. Convincing evidence disputing a role for this gene in this disease has arisen since the initial report identifying an association between the gene and disease. b. Refuting evidence need not outweigh existing evidence supporting the gene:disease association.
Refuted
a. Evidence refuting the role of the gene in the specified disease has been reported and significantly outweighs any evidence supporting the role. b. This designation is to be applied at the discretion of clinical domain experts after thorough review of available evidence
NOTES
Figure 2
Case-Level Data 
12
Proband with predicted or proven null variant 3 1.5 0-2
10
Proband with other variant type with some evidence of gene impact 4 0.5 0-1.5
Autosomal Recessive
Two variants in trans and at least one de novo 2 or a predicted/proven null variant 3 2 0-3
12
Two variants (not predicted/proven null) with some evidence of gene impact 4 in trans 1 0-1.5
Segregation Evidence
Evidence of segregation in one or more families 5 
LOD
TOTAL ALLOWABLE POINTS for Genetic Evidence 12
General Notes
• Detailed guidance for utilizing this scoring matrix is available on the ClinGen website in the standard operating procedure.
• All variants under consideration should be rare enough in the general population to be consistent with disease.
• Cohorts/cases should not be double counted. For example, individual cases included as part of case-control studies should not be given points from both the "Case Level Data" and "Case-Control Data" categories. • Case-Level Data includes studies describing individuals or families with variation in the gene of interest • Case-Control studies are those in which statistical analysis is used to evaluate variation in cases compared to controls. 
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